BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths- Independence from the rat race for Recent college grads: Systems and Tips
- Iran denies launching ballistic missiles towards Kurdistan region of Iraq
- Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- Inconceivable Spots To Stargaze All over The Planet
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
